Inhibikase Therapeutics Inc (IKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -9,281 | -4,641 | -14,786 | -9,744 | -5,273 |
| Accounts receivable | 104 | 62 | -110 | -218 | -587 |
| Accounts payable and accrued liabilities | -229 | -284 | -631 | -1,167 | -838 |
| Other Working Capital | 668 | 516 | -1,765 | -2,415 | -4,331 |
| Other Operating Activity | 449 | 412 | 2,995 | 3,342 | 2,848 |
| Operating Cash Flow | $-8,290 | $-3,934 | $-14,297 | $-10,201 | $-8,181 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -43 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $-43 | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -249 | -249 | -43 | -43 | -43 |
| Common Stock Issued | 44 | 44 | 41,214 | 41,214 | 41,184 |
| Other Financing Activity | 0 | 0 | -78 | -78 | -78 |
| Financing Cash Flow | $-205 | $-205 | $41,094 | $41,094 | $41,064 |
| Beginning Cash Position | 40,750 | 40,750 | 13,954 | 13,954 | 13,954 |
| End Cash Position | 32,212 | 36,611 | 40,750 | 44,846 | 46,837 |
| Net Cash Flow | $-8,538 | $-4,139 | $26,797 | $30,892 | $32,883 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,290 | -3,934 | -14,297 | -10,201 | -8,181 |
| Capital Expenditure | -43 | N/A | N/A | N/A | N/A |
| Free Cash Flow | -8,333 | -3,934 | -14,297 | -10,201 | -8,181 |